Johnson & Johnson JNJ

$262.87 +1.43 (0.55%)

Valuation

Market cap
630,043,712,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
23.62
Forward PE
22.95
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
2,670,434
Avg volume
6,565,684
Day's range
$260.37 – $263.32
Shares out
2,409,898,000
Stochastic %K
50%
Beta
0.21
Analysts
Strong Sell
Price target
$282.76

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

SellasgpsCurativeBAT11 Oct 12, 5:44 PM
$SLS $JNJ $PFE $MRK $BMY GPS Groundbreaking results which show a huge difference between GPS and BAT, potentially approaching transplant survival rates without the huge risks/recovery, means that expansion within AML is all but guaranteed, and expansion into other 20+ cancers that can achieve low disease burden will immediately be followed up on. In this scenario, letting a rival pharma company acquire SLS comes with pretty big risks, so a bidding war becomes increasingly likely. I would expect an acquisition to follow fairly quickly in this scenario, probably within a few days of results, because Sellas would be very happy to accept the best offer they receive, and whoever the bidder is would want full control over the BLA application and subsequent expansion of further trials ASAP. They would likely be willing to pay the sort of values that get thrown around here based on the expected returns, and Sellas would be very happy to accept an offer! ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 12, 5:40 PM
$BMY $JNJ $MRK $PFE $SLS GPS Groundbreaking results which show a huge difference between GPS and BAT, potentially approaching transplant survival rates without the huge risks/recovery, means that expansion within AML is all but guaranteed, and expansion into other 20+ cancers that can achieve low disease burden will immediately be followed up on. In this scenario, letting a rival pharma company acquire SLS comes with pretty big risks, so a bidding war becomes increasingly likely. I would expect an acquisition to follow fairly quickly in this scenario, probably within a few days of results, because Sellas would be very happy to accept the best offer they receive, and whoever the bidder is would want full control over the BLA application and subsequent expansion of further trials ASAP. They would likely be willing to pay the sort of values that get thrown around here based on the expected returns, and Sellas would be very happy to accept an offer! ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 12, 5:32 PM
$SLS $JNJ $MRK $PFE $AZN Looking at 2 year PR history Tuesday is #1 PR day for Sellas Life Sciences. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 12, 5:25 PM
$BMY $SLS $JNJ $BMY Part 3. I have to BO scenario Analysis 1. Pre Public Data readout BO under strict NDA= $120.00+ 2. Post data BO Bidding War post public release= $240.00+ Good Bye Shorts it’s GME all over again as in either scenario all your short accounts will be liquidated by your brokerage firms. Time to cover is about to run out in t- 24 hours. ✌️🙏❤️‍🩹
0 replies
eWhispers Oct 12, 4:58 PM
Earnings scheduled before the open on Tuesday, October 13, 2026 https://www.earningswhispers.com/calendar $UNH $JPM $GS $WFC $JNJ
0 replies
BioRich Oct 12, 3:54 PM
$SLS Anyone have a list of Companies this board is going to pump as the company Buying $SLS? $IBRX, $MRNA, $MRK, $JNJ. Which one is getting pumped next. I'm sure the Rope Hats have the next 3 picked out and I want in before the pump.
1 replies
27R Oct 12, 3:04 PM
$JNJ Buckle up — earnings before the open tomorrow.
0 replies
SellasgpsCurativeBAT11 Oct 12, 1:16 PM
$AZN $JNJ $SLS $ABBV Johnson & Johnson (JNJ) is scheduled to report its third-quarter 2026 earnings on Tuesday, October 13, 2026, before the market opens (around 6:45 AM ET). Let’s see if JNJ is the suitor, we will find out in less than 24 hours. Cavanaugh has been at the helm of J&J division that will consummate Sellas deal for over a month now. ✌️🙏❤️‍🩹
1 replies